JCI: STAT3 Inhibitor May Provide New Hope for Leukemia Treatment

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are malignant hematopoietic stem cell disorders, and abnormal stem cell populations in hematopoietic stem and progenitor cells can cause disease. Traditional treatments to date can not completely eliminate these abnormal hematopoietic stem cells associated with the disease.   Recently, researchers from the Albert Einstein College of Medicine have discovered a prognosis molecule that predicts both MDS and AML. Furthermore, an antisense oligonucleotide…

Read More >>